+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Subdermal Contraceptive Implants Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 5026034
  • Report
  • May 2020
  • Region: Global
  • 60 pages
  • Mordor Intelligence
until Sep 30th 2021


  • Bayer AG
  • Merck Sharp & Dohme Corp.
The Subdermal Contraceptive Implants market studied is anticipated to grow with a CAGR of nearly 3.5%, during the forecast period. Certain factors that are driving the market growth include the rise in the number of initiatives to promote contraceptive methods and the increasing number of unwanted pregnancies. The number of unwanted pregnancies is increasing globally and it is a matter of serious concern all around the world.

As per the WHO 2019 report, Globally, 74 million women living in low and middle-income countries have unintended pregnancies annually. This leads to 25 million unsafe abortions and 47000 maternal deaths every year. According to the centers for disease control and prevention, in 2017, it was estimated that about 194,377 babies were born to women, aged 15-19 years, for a birth rate of 18.8 per 1,000 women, in this age group. Hence, with the increasing rate of unintended pregnancies, there will be a rapid increase in the demand for contraceptive devices, which will ultimately drive the market.

Furthermore, there are countries and their respective governments that have identified the need to curb the growth of unwanted pregnancies and have started a great number of initiatives to educate and prevent the spread of unwanted abortions and pregnancies. The usage of contraceptive pills is one among them. The right to obtain and use contraceptives is part of the fundamental right to privacy guaranteed by the United States Constitution. Thus, government initiatives are also promoting the use of contraceptives to avoid the unnecessary births.

Key Market Trends

Etonogestrel Implant Holds Significant Market Share in the Global Subdermal Contraceptive Implants Market
  • Etonogestrel is a hormone which prevents ovulation. This medication also causes changes in your cervical mucus and uterine lining, making it harder for sperm to reach the uterus and harder for a fertilized egg to attach to the uterus.
  • Subdermal Etonogestrel implant is used as contraception to prevent pregnancy. The medicine is contained in a small plastic rod that is implanted under the skin of upper arm. The medicine is released slowly into the body. The rod can remain in place and provide continuous contraception for up to 3 years.
North America Dominates the Global Subdermal Contraceptive Implants Market
  • North America is expected to register high growth, owing to the presence of sophisticated healthcare infrastructure, the high adoption rate of contraceptive drugs, and the rising number of government initiatives that help in increasing the overall market.
  • A large section of the women population represents the reproductive age in the United States as well as Canada. With that, a significant size of the population is at risk of unintended pregnancy, as their partners do not use a contraceptive method, correctly and consistently.
  • The awareness regarding these products is also high with considerable support being provided by several hospitals to control the patients affected by its misuse. Moreover, the distribution channel of several companies is well established across the United States and Canada, which overall drives the market and contributes to the largest share, over the forecast period.
Competitive Landscape

The global Subdermal Contraceptive Implants market is competitive and consists of very few major players. Companies like Merck Sharp & Dohme Corp., Shanghai Dahua Pharmaceutical Co., Ltd., Bayer AG, hold a substantial market share in the market.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • Bayer AG
  • Merck Sharp & Dohme Corp.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the Number of Initiatives to Promote Contraceptive Methods
4.2.2 Increasing Number of unwanted pregnancies
4.3 Market Restraints
4.3.1 Rising Prevalence of Infertility
4.3.2 Lack of Awareness and Adverse Effects of Contraceptive Implants
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type
5.1.1 Etonogestrel Implant
5.1.2 Levonorgestrel Implant
5.2 Geography
5.2.1 North America
5.2.2 Europe
5.2.3 Asia-Pacific
5.2.4 Rest of World

6.1 Company Profiles
6.1.1 Merck Sharp & Dohme Corp.
6.1.2 Shanghai Dahua Pharmaceutical Co., Ltd.
6.1.3 Bayer AG

Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Merck Sharp & Dohme Corp.
  • Shanghai Dahua Pharmaceutical Co., Ltd.
  • Bayer AG
Note: Product cover images may vary from those shown